1405 todd manning
TRANSCRIPT
“The AbbVie oncology products are all investigational in nature and are currently not licensed in any country. The ultimate licensing of these compounds is subject to regulatory review and approval.”
2
AbbVie Oncology Vision
We will accomplish this by:• Leveraging our leading-edge platforms• Working closely with academia, diagnostic companies and cooperative
groups• Bringing to market novel therapeutics with transformational increases in
efficacy and safety
Transform the Lives of People with Cancer
It starts with science……and continues with AbbVie’s commitment to research and development
3
Oncology is a new focus for AbbVie
AbbVie has a rich oncology pipeline in more than 15 different tumour types
AbbVie’s late phase pipeline includes treatments for both haematological malignancies and solid tumours
4
Phase 17 molecules
Phase 21 molecule
Phase 33 molecules
PARP inhibitor(solid tumours)
potential indications6
Phase 2/3 trials19
BCL-2 inhibitor(haem malignancies)
potential indications6
Phase 2/3 trials7
EGFR ADC(glioblastoma)
potential indications2
Phase 2/3 trials2
PI3K inhibitor(haem malignancies)
potential indications6
Phase 2/3 trials10
5
Global Trials in Solid Tumours
Brain Metastases Breast NSCLC SCLC Colorectal Ovarian Gastric Glioblastoma
In 2014 - • ~1100 subjects enrolled in Phase 1-3 trials• ~60 trials performed across multiple tumours• Studies conducted in 44 countries
AbbVie’s oncology clinical development is founded on deep scientific and clinical expertise
Global Trials in Haem. Malignancies
Acute Myelogenous Leukemia Chronic Lymphocytic Leukemia Multiple Myeloma Non-Hodgkin’s Lymphoma
Current Trials in Ireland
Squamous non-small cell lung cancer Glioblastoma
Manufacturing in Ireland: 2 of AbbVie’s 3 oncology compounds in phase 3 trials are manufactured in Ireland
• Each of the uniquely focused sites in Ireland manufactures portions of AbbVie’s top 20 products
• The company has 12 sites in total across the United States, Europe and Puerto Rico, as well as strategic partnerships with third-party manufacturers
• Of the 3 oncology compounds in phase 3 trials, 2 are manufactured in Ireland
6
In addition to organic development of new compounds, AbbVie is also investing heavily in the oncology pipeline
7
Summary
• AbbVie is new to oncology, and has a number of compounds in pre-clinical, early phase and late phase development
• Late phase trials include both solid tumours and haematological malignancies, and enrolled over 1100 patients in 2014
• AbbVie is investing in acquisitions and licensing compounds, in addition to the discovery and development process
8